empoweringmuscleempoweringlives
We are developing muscle biology-directed potential medicines to improve the healthspan of people with devastating diseases of impaired muscle function
and conditions of muscle weakness
associated with aging.
Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
Advancement of Second Novel Mechanism Cardiac Sarcomere Activator Reinforces Leadership Position in Muscle Directed Pharmacology SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first subject has been dosed in a Phase...
READ MORE ›als
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart Failure
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
sma
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.